TUDCA combined with Syndopa protects the midbrain and gut from MPTP toxicity in a Parkinson’s disease mouse model: Immunohistochemical evidence
Biomolecules and Biomedicine · 04.08.2025 · 25 (12) · 2776-2788
DOI: 10.17305/bb.2025.12519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 04.08.2025. Verfasst von Mahalakshmi Rajan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, Saveetha Institute of Medical and Technical Sciences, Chennai, India; Department of Anatomy, Sri Muthukumaran…. Hauptthemen laut MEDLINE: Taurochenodeoxycholic Acid, Mesencephalon, Parkinson Disease, Levodopa. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neuro-inflammation plays a significant role in the neurodegenerative processes associated with Parkinson's disease (PD). A hallmark of PD is the degeneration of dopaminergic neurons within the nigrostriatal pathway. The standard treatment for PD is Syndopa (a combination of levodopa and carbidopa). However, while Syndopa alleviates symptoms, it is also associated with numerous side effects in patients. Research has demonstrated the protective effects of Tauroursodeoxycholic acid (TUDCA) in mitigating the neuropathological consequences of PD in several preclinical studies. Nonetheless, further investigation is necessary to delineate the role of TUDCA in PD therapeutics. Although the efficacy of TUDCA monotherapy in PD has been explored, there is a lack of preclinical research examining the additive effects of TUDCA in conjunction with Syndopa therapy. In this study, we utilized an MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of PD to evaluate the potential therapeutic benefits of TUDCA monotherapy and the combined effects of TUDCA and Syndopa therapy, compared to standard Syndopa treatment. We conducted immunohistochemical (IHC) assessments of α-synuclein expression in the gut and substantia nigra pars compacta (SNpc), as well as tyrosine hydroxylase and NF-kB expression in the striatum and SNpc regions, to investigate the efficacy of the test drugs. The immunohistochemical findings indicate that both TUDCA monotherapy and the combination therapy of TUDCA and Syndopa significantly reduced MPTP-induced alterations in the expression levels of α-synuclein, tyrosine hydroxylase, and NFκB in the striatum and SNpc regions. Additionally, the MPTP-induced changes in α-synuclein expression in the gut were notably reversed by these treatments. Collectively, these results suggest that incorporating TUDCA with Syndopa may represent a promising therapeutic strategy to address the pathophysiological challenges associated with PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Research and Development, Saveetha Institute of Medical and Technical Sciences, Chennai, India; Department of Anatomy, Sri Muthukumaran Medical College and Research Institute, Chennai, India.
- Department of Research and Development, Saveetha Institute of Medical and Technical Sciences, Chennai, India.
- Department of Anatomy, Sri Ramachandra Medical College and Research Institute, Chennai, India.
- Department of Biotechnology, Central University of Rajasthan, Ajmer, India.
- Department of Anatomy, KMCH Institute of Health Sciences and Research, Coimbatore, India.
- Baylor College of Medicine, Houston, Texas, USA.
Zitieren
APA
Rajan, M., Sivanesan, S., Ramachandran, K., Goyal, P., Palanivelu, P., Ghosh, A., Vijayaraghavan, R., & Vasavan, S. S. (2025). TUDCA combined with Syndopa protects the midbrain and gut from MPTP toxicity in a Parkinson’s disease mouse model: Immunohistochemical evidence. Biomolecules and Biomedicine, 25(12), 2776-2788. https://doi.org/10.17305/bb.2025.12519
Vancouver
Rajan M, Sivanesan S, Ramachandran K, Goyal P, Palanivelu P, Ghosh A, et al. TUDCA combined with Syndopa protects the midbrain and gut from MPTP toxicity in a Parkinson’s disease mouse model: Immunohistochemical evidence. Biomolecules and Biomedicine. 2025;25(12):2776-2788. doi:10.17305/bb.2025.12519
BibTeX
@article{Rajan2025,
author = {Rajan, Mahalakshmi and Sivanesan, Senthilkumar and Ramachandran, Kalpana and Goyal, Pankaj and Palanivelu, Priya and Ghosh, Anamitra and Vijayaraghavan, Rajagopalan and Vasavan, Smitha S},
title = {TUDCA combined with Syndopa protects the midbrain and gut from MPTP toxicity in a Parkinson’s disease mouse model: Immunohistochemical evidence},
journal = {Biomolecules and Biomedicine},
year = {2025},
volume = {25},
number = {12},
pages = {2776--2788},
doi = {10.17305/bb.2025.12519}
}
EUVIMED